Published 4 days ago • loading... • Updated 3 days ago

FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra

Summary by Managed Healthcare Executive

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

5 Articles

All

Left

Center

Right

pharmtech.com

EMA Recommends Five New Medicines for Approval

Three of the five are biosimilars, and seven additional medicines received recommendations for indication extensions.

3 days ago

Read Full Article

Anti-Aging, Acupuncture and Health News

FDA Approves Fourth Denosumab Biosimilar

The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference product denosumab (Prolia/Xgeva). The biosimilar will launch in the United States in June 2025 as part of a global settlement with Amgen, which manufactures the reference product. The higher dosage of denosumab-bnht (Bomyntra; 120 […] The post FDA Approves Fourth Denosumab Biosimilar f…

4 days ago

Read Full Article

Managed Healthcare Executive

FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra

4 days ago

Read Full Article

centerforbiosimilars.com

FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

4 days ago

Read Full Article